At Ankhero, we encourage dialogue across the pharmaceutical and supply chain ecosystem. In this section, you’ll find our podcasts, expert insights, and commentary on key industry topics – from regulatory developments to technology and operational challenges – helping professionals stay informed and make better decisions.
The Next Phase of Pharma Serialisation by Ankhero Insights In 2019, serialisation decisions were made in a state of urgency.In 2026, those same decisions are being revisited in a state
Common Sense vs. Nonsense: A Teardown of “Artificial Expert Intelligence” By JJS Ahdan I recently read an article by Shabir Dahod titled “Could Artificial Expert Intelligence Fix Pharma’s Supply Chain
For companies working in regulated environments, validation is non-negotiable. What happens when the tool you’re relying on starts becoming part of the problem. Delivering meaningful value, or simply the illusion
National Bottlenecks If you’re resolving alerts without involving your NMVO, or worse, relying solely on EMVO – you’re working uphill. When the EU’s Falsified Medicines Directive went live, it promised
Are Pfizer leaving them? Seems likely from the attached job posting. A bold move, for sure, but one can only assume there is confidence that change is necessary to leave
We discuss the signifcance (or insignificance) that was Nov 27, 2023. What do companies need to know going forward as well as a look back on the last 10 years
This week we talk about a service offering from Jennason called doss digital which helps companies leverage no code/low code technology to build business applications that solve business challenges quickly
We are back with episode 5 of the Saying the Quiet Things Out Loud Podcast. Today we discuss how one single email can provide significant insight into your serialization vendor’s
2 quick takes and the announcement of the Jennason DSCSA Trading Partner Directory Introduction Quick Take #1- DSCSA ‘stabilization’: Don’t let vendors fool you into rushing Quick Take #2: NABP
The FDA has announced a 1 Year enforcement description to the upcoming November DSCSA deadline. In today’s episode we discuss: A summary of the enforcement discretion What additional details companies
Episode 2 of the Saying The Quiet Things Out Loud podcast. Part 1 The next 30 days. What pharma entities need to watch for related to DSCSA Why companies should
The first installment of the Saying The Quiet Things Out Loud Podcast where we will focus on current topics and trends in the pharmaceutical serialization space. In today’s episode we
On Oct 9, 2024 the FDA announced further delays to the milestone of the DSCSA regulation. The new dates give manufacturers 6 additional months, wholesalers 9 additional months and non